Cargando…

Nelfinavir: An Old Ally in the COVID-19 Fight?

After almost three years of the pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still spreading around the world, causing notable sanitary and social issues. New antiviral therapies are constantly under investigation. However, few options have been approved for the treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gidari, Anna, Sabbatini, Samuele, Pallotto, Carlo, Bastianelli, Sabrina, Pierucci, Sara, Busti, Chiara, Schiaroli, Elisabetta, Francisci, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783559/
https://www.ncbi.nlm.nih.gov/pubmed/36557724
http://dx.doi.org/10.3390/microorganisms10122471
_version_ 1784857605975310336
author Gidari, Anna
Sabbatini, Samuele
Pallotto, Carlo
Bastianelli, Sabrina
Pierucci, Sara
Busti, Chiara
Schiaroli, Elisabetta
Francisci, Daniela
author_facet Gidari, Anna
Sabbatini, Samuele
Pallotto, Carlo
Bastianelli, Sabrina
Pierucci, Sara
Busti, Chiara
Schiaroli, Elisabetta
Francisci, Daniela
author_sort Gidari, Anna
collection PubMed
description After almost three years of the pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still spreading around the world, causing notable sanitary and social issues. New antiviral therapies are constantly under investigation. However, few options have been approved for the treatment of COVID-19. Clinical trials are currently ongoing to evaluate the efficacy of nelfinavir on mild–moderate COVID-19. This study aims to investigate the activity of this compound on SARS-CoV-2 “Variants of Concern” (VOCs), comparing its effectiveness with the approved drugs remdesivir and molnupiravir. The experiments were conducted in a biosafety level 3 facility. In this study, we used a Vero-E6-cell-based infection assay to investigate the in vitro activity of nelfinavir, molnupiravir, and remdesivir. Four strains of SARS-CoV-2 were tested: 20A.EU1, B.1.1.7, P.1, and B.1.617.2. All compounds reached micromolar/submicromolar EC50, EC90, and EC99. Furthermore, the Cmax/EC50 and Cmax/EC90 ratios were >1 for all compounds and all variants tested. Our study demonstrated that nelfinavir, as molnupiravir, and remdesivir are effective in vitro on SARS-CoV-2 variants.
format Online
Article
Text
id pubmed-9783559
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97835592022-12-24 Nelfinavir: An Old Ally in the COVID-19 Fight? Gidari, Anna Sabbatini, Samuele Pallotto, Carlo Bastianelli, Sabrina Pierucci, Sara Busti, Chiara Schiaroli, Elisabetta Francisci, Daniela Microorganisms Article After almost three years of the pandemic, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is still spreading around the world, causing notable sanitary and social issues. New antiviral therapies are constantly under investigation. However, few options have been approved for the treatment of COVID-19. Clinical trials are currently ongoing to evaluate the efficacy of nelfinavir on mild–moderate COVID-19. This study aims to investigate the activity of this compound on SARS-CoV-2 “Variants of Concern” (VOCs), comparing its effectiveness with the approved drugs remdesivir and molnupiravir. The experiments were conducted in a biosafety level 3 facility. In this study, we used a Vero-E6-cell-based infection assay to investigate the in vitro activity of nelfinavir, molnupiravir, and remdesivir. Four strains of SARS-CoV-2 were tested: 20A.EU1, B.1.1.7, P.1, and B.1.617.2. All compounds reached micromolar/submicromolar EC50, EC90, and EC99. Furthermore, the Cmax/EC50 and Cmax/EC90 ratios were >1 for all compounds and all variants tested. Our study demonstrated that nelfinavir, as molnupiravir, and remdesivir are effective in vitro on SARS-CoV-2 variants. MDPI 2022-12-14 /pmc/articles/PMC9783559/ /pubmed/36557724 http://dx.doi.org/10.3390/microorganisms10122471 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gidari, Anna
Sabbatini, Samuele
Pallotto, Carlo
Bastianelli, Sabrina
Pierucci, Sara
Busti, Chiara
Schiaroli, Elisabetta
Francisci, Daniela
Nelfinavir: An Old Ally in the COVID-19 Fight?
title Nelfinavir: An Old Ally in the COVID-19 Fight?
title_full Nelfinavir: An Old Ally in the COVID-19 Fight?
title_fullStr Nelfinavir: An Old Ally in the COVID-19 Fight?
title_full_unstemmed Nelfinavir: An Old Ally in the COVID-19 Fight?
title_short Nelfinavir: An Old Ally in the COVID-19 Fight?
title_sort nelfinavir: an old ally in the covid-19 fight?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9783559/
https://www.ncbi.nlm.nih.gov/pubmed/36557724
http://dx.doi.org/10.3390/microorganisms10122471
work_keys_str_mv AT gidarianna nelfinaviranoldallyinthecovid19fight
AT sabbatinisamuele nelfinaviranoldallyinthecovid19fight
AT pallottocarlo nelfinaviranoldallyinthecovid19fight
AT bastianellisabrina nelfinaviranoldallyinthecovid19fight
AT pieruccisara nelfinaviranoldallyinthecovid19fight
AT bustichiara nelfinaviranoldallyinthecovid19fight
AT schiarolielisabetta nelfinaviranoldallyinthecovid19fight
AT franciscidaniela nelfinaviranoldallyinthecovid19fight